CD4 and tuberculosis: Comparing CASTLE trial participants with a previous trial of TB screening (STAMP: 2015–2017) recruiting at the same hospital and with the same eligibility criteria, we observed lower number of daily admissions to medical wards for PHIV, fewer people not on ART (20% STAMP, 8% CASTLE), but relatively similar low CD4 counts (median CD4 219 cells/mm3 STAMP, 240 cells/mm3 CASTLE).